Fingerprint
Dive into the research topics of 'Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC
Arkadiusz Z. Dudek, Priya Kumar, Sunn Sunn H. Thaw, Qing Cao, Pamala Pawloski, Timothy Larson
Research output: Contribution to journal › Article › peer-review
4
Scopus
citations